Deal-Making

Terumo and BioCentriq to drive automated CGT manufacturing

BioCentriq’s laboratories will be equipped with Terumo’s technologies to accelerate the adoption of automated production for cell and gene therapies. Apheresis services firm Terumo Blood and Cell Technologies and cell and gene therapy contract development manufacturing organization (CDMO) BioCentriq have entered a strategic collaboration to bring cell and gene therapies (CGT) to individuals more quickly and cheaper. “This agreement will expand customer reach by introducing early-stage CGT researchers and developers to the benefits of manufacturing automation and demonstrating how to…

Aceto buffers up presence in bioprocessing with A&C buy

A&C Bio Buffer is the sixth acquisition for Aceto in the past two years and signals the firm’s ambitions in the biomanufacturing services space. The deal, financials of which have not been disclosed, brings Aceto a GMP (Good Manufacturing Practices) manufacturer of custom buffer and chemical blend products used in the manufacturing of biopharmaceutical drug products, with a facility in Limerick, Ireland producing over 50 products including biological buffers, process solutions, cleaning solutions and WFI (Water for Injection). “A&C Bio…

Ins and outs: High level changes at BlueRock, Pfizer and the NIH

Emile Nuwaysir has stepped down from his position as CEO of BlueRock and moves to in vivo cell therapy firm Ensoma. Meanwhile, there are changes at Pfizer and the National Institutes of Health (NIH). Nuwaysir has been CEO of Bayer’s subsidiary BlueRock Therapeutics since 2017. Since then, the company has transitioned from a preclinical start-up to a clinical-stage firm that employs over 200 people across two countries. Nuwaysir will remain at the company as a board chair and continue to…

Simulated Bed fellows: Tosoh buys purification firm Semba

Tosoh Bioscience says it will complement its resins business through the addition of continuous chromatography firm Semba Biosciences. The deal, which closed earlier this month, saw Pennsylvania-based Tosoh add all Semba’s staff and assets for an undisclosed fee. The acquisition will boost the firm’s downstream bioproduction portfolio, made up of chromatography resins, with the addition of Semba’s simulated moving bed (SMB) chromatography systems (see text box below). “Coupled with Semba’s revolutionary multi-column chromatography technology we have found a perfect complement…

ViroCell partnership to double UK lentivirus vector capacity

ViroCell has partnered with Great Ormond Street Hospital to address the global viral vector manufacturing bottleneck for clinical trials. Contract development manufacturing organization (CDMO) ViroCell Biologics says its partnership with Great Ormond Street Hospital (GOSH) will more than double the UK’s lentivirus vector manufacturing capacity for clinical trials in 2022. Additionally, ViroCell claims the collaboration will secure its position as the first CDMO in the UK to deliver adeno-associated viruses (AAV) vectors to the cell and gene therapy (CGT) markets.…

Gamma invests in bio-sensor and analytics firm Nirrin

Nirrin’s near-infrared spectrometry platform offers a reliable and cost-effective method of real-time analytics and will be leveraged across Gamma’s growing bioprocessing network, the firms says. Gamma Biosciences’s undisclosed investment in Maryland-based Nirrin Technologies brings access to sensors and analytics that support the bioprocess space, including automation tech with real-time, in-process monitoring for upstream and downstream applications. “This is a structured investment with longer term features that allow Nirrin to leverage Gamma’s resources and network in the near term as the…

Boston Labs and Germfree launch mobile CGT platform

Boston Labs and Germfree Laboratories have partnered to launch a mobile cell and gene therapy (CGT) manufacturing platform in Boston, US. The partnership between clinical logistics firm, Boston Labs, and manufacturer of mobile and modular laboratories, Germfree, aims to reduce client CGT production expenses and complexities by delivering access to mobile manufacturing facilities wherever they are required. The CGT mobile manufacturing platform will be launched in the fourth quarter of 2021 in Boston, Massachusetts offering a decentralized cell and gene therapy…

Novartis boosts optogenetics portfolio with Arctos buy

Novartis will bolster is adeno-associated virus (AAV) gene therapy-based options for different forms of blindness through the acquisition of Arctos Medical. Swiss pharma giant Novartis has acquired gene therapy firm Arctos for an undisclosed fee, gaining one pre-clinical optogenetic AAV gene therapy program and its technology platform. Optogenetics uses light to modulate molecular events in a targeted manner in organisms or living cells and according to Novartis the acquisition supports its commitment to using optogenetics-based therapies to restore vision to patients…

Serum Institute invests $68m in Oxford Biomedica to expand vector capacity

Oxford Biomedica will add 39,000 square feet of advanced manufacturing space at its Oxbox site in the UK following an investment from the Serum Institute of India. The £50 million ($68 million) investment from Indian vaccine giant Serum Institute of India will be used to develop the fallow area at Oxford Biomedica’s ‘Oxbox’ viral vector manufacturing site in Oxford, UK. In return, Serum Institute of India – through its subsidiary Serum Life Sciences – will acquire a 3.9% stake in…

Moderna and AbCellera join forces to develop antibody therapies

Moderna’s mRNA technology platform will be combined with AbCellera’s AI-powered antibody discovery platform to develop mRNA-encoded antibody therapeutics. The multi-year deal, of which financial details have not been disclosed, will see Moderna use AbCellera’s antibody discovering platform to search and examine natural immune responses to identify therapeutic antibodies against up to six targets. AbCellera’s platform will be combined with Moderna’s messenger RNA (mRNA) technology platform with a shared aim of accelerating the development of mRNA-encoded antibody therapeutics. Under the terms…